Ernexa Therapeutics (ERNAW) Other Accumulated Expenses (2010 - 2026)

Ernexa Therapeutics has reported Other Accumulated Expenses for 17 years, with the latest figure at $218000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses fell 52.61% year-over-year to $218000.0; the trailing twelve-month figure through Mar 2026 stood at $218000.0 (down 52.61% YoY), and the FY2025 full-year result was $83000.0, down 63.27% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $218000.0, up from $83000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.6 million in Q3 2022, with the low at $45000.0 in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $588764.7 across 5 years, with a median of $508000.0 in 2023.
• The largest YoY upside for Other Accumulated Expenses was 1055.56% in 2023 against a maximum downside of 78.1% in 2023.
• Ernexa Therapeutics' Other Accumulated Expenses stood at $590000.0 in 2022, then retreated by 13.9% to $508000.0 in 2023, then slumped by 55.51% to $226000.0 in 2024, then sank by 63.27% to $83000.0 in 2025, then surged by 162.65% to $218000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $218000.0 (Q1 2026), $83000.0 (Q4 2025), and $139000.0 (Q3 2025), per Business Quant data.